Drs Cheryl Lee and Tom Powles talk about ctDNA and personalized medicine approaches for advanced bladder cancer as we sit at the precipice of change.

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/987106). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Circulating Tumor DNA: A Promising Biomarker in the Liquid Biopsy of Cancer https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217053/

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy (IMvigor011) https://clinicaltrials.gov/ct2/show/NCT04660344

A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection (IMvigor010) https://clinicaltrials.gov/ct2/show/NCT02450331